Key Points Question Is convalescent plasma useful in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia? Findings In this randomized clinical trial of 487 patients with COVID-19 pneumonia and a partial pressure of arterial oxygen–to–fraction of inspired oxygen (Pa o 2 /Fi o 2 ) ratio between 350 and 200 mm Hg at enrollment, the rate of the primary clinical end point (need for mechanical ventilation, defined as Pa o 2 /Fi o 2 ratio <150 mm Hg, or death) was not significantly different between the convalescent plasma group and the control group. Meaning In this trial, convalescent plasma did not reduce the progression to severe respiratory failure or death within 30 days. This randomized clinical trial evaluates the efficacy of convalescent plasma plus standard therapy vs standard care alone in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia. Importance Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia. Objective To evaluate the efficacy of CP plus standard therapy (ST) vs ST alone in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia. Design, Setting, and Participants This prospective, open-label, randomized clinical trial enrolled (1:1 ratio) hospitalized patients with COVID-19 pneumonia to receive CP plus ST or ST alone between July 15 and December 8, 2020, at 27 clinical sites in Italy. Hospitalized adults with COVID-19 pneumonia and a partial pressure of oxygen–to–fraction of inspired oxygen (Pa o 2 /Fi o 2 ) ratio between 350 and 200 mm Hg were eligible. Interventions Patients in the experimental group received intravenous high-titer CP (≥1:160, by microneutralization test) plus ST. The volume of infused CP was 200 mL given from 1 to a maximum of 3 infusions. Patients in the control group received ST, represented by remdesivir, glucocorticoids, and low–molecular weight heparin, according to the Agenzia Italiana del Farmaco recommendations. Main Outcomes and Measures The primary outcome was a composite of worsening respiratory failure (Pa o 2 /Fi o 2 ratio <150 mm Hg) or death within 30 days from randomization. Results Of the 487 randomized patients (241 to CP plus ST; 246 to ST alone), 312 (64.1%) were men; the median (IQR) age was 64 (54.0-74.0) years. The modified intention-to-treat population included 473 patients. The primary end point occurred in 59 of 231 patients (25.5%) treated with CP and ST and in 67 of 239 patients (28.0%) who received ST (odds ratio, 0.88; 95% CI, 0.59-1.33; P = .54). Adverse events occurred more frequently in the CP group (12 of 241 [5.0%]) compared with the control group (4 of 246 [1.6%]; P = .04). Conclusions and Relevance In patients with moderate to severe COVID-19 pneumonia, high-titer anti–SARS-CoV-2 CP did not reduce the progression to severe respiratory failure or death within 30 days. Trial Registration ClinicalTrials.gov Identifier: NCT04716556
【초록키워드】 convalescent plasma, randomized clinical trial, Glucocorticoids, Efficacy, Severe COVID-19 pneumonia, COVID-19 pneumonia, clinical trial, Respiratory failure, Trial, Open-label, randomization, mechanical ventilation, Pneumonia, severe respiratory failure, Remdesivir, oxygen, progression, Italy, hospitalized patients, heparin, adverse events, Registration, Patient, death, plasma, age, patients, Microneutralization test, recommendations, Standard therapy, Odds ratio, Composite, intravenous, moderate to severe, partial pressure, Volume, Enrollment, Low–molecular weight heparin, Adverse, Primary outcome, control group, 95% CI, standard care, experimental group, worsening, measure, CP group, maximum, participant, primary end point, treat, convalescent plasma group, CP plus standard therapy, fraction, high-titer anti–SARS-CoV-2 CP, moderate to severe COVID-19 pneumonia, volume of infused CP, worsening respiratory failure, finding, objective, setting, event, modified intention-to-treat, Result, enrolled, defined, evaluate, occurred, treated, hospitalized patient, did not reduce, Importance, receive, 1:1, clinical end point, CP and ST, CP plus ST, eligible, high-titer CP, infused, IQR, not significantly different, patients with COVID-19, patients with moderate, Point, randomized patient, Relevance, ST alone, the median, with COVID-19, 【제목키워드】 COVID-19, clinical, respiratory, failure, Effect,